2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Treatment Considerations, Drug Development, Biological Therapies, Transplantation, Gene Therapy, Adverse Events, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Research, Fundamental Science, Translational Research, Clinical Research, Epidemiology, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

1141 A novel mouse model of sickle cell (SS) and global CYB5R3 T117S expression: Exploring interindividual differences in SS-associated pulmonary hypertension

Katherine C Wood, PhD, Scott Hahn, MS2, Stefanie Taiclet3, Fabliha Ahmed Chowdhury, MPharm, PhD4, Megan Miller5, Brett Kaufman, PhD6, Adam Straub, PhD7
1 University Of Pittsburgh, Pittsburgh, Pennsylvania, United States
2 University Of Pittsburgh, Pittsburgh, Pennsylvania, United States
3 University Of Pittsburgh, Pittsburgh, Pennsylvania, United States
4 University Of Pittsburgh, Pittsburgh, Pennsylvania, United States
5 University Of Pittsburgh, Pittsburgh, Pennsylvania, United States
6 University Of Pittsburgh, Pittsburgh, Pennsylvania, United States
7 University Of Pittsburgh, Pittsburgh, Pennsylvania, United States

Background: Cytochrome b5 reductase 3 (CYB5R3) functions to maintain the soluble guanylate cyclase (sGC) heme iron in a reduced state (Fe2+) for sensing nitric oxide (NO), which signals for cyclic guanosine monophosphate (cGMP) production and protein kinase G (PKG)-mediated vasorelaxation.  CYB5R3 T117S (rs 1800457) is a missense variant with high frequency (23% MAF) expression in persons of African ancestry and rarity in other races (<1%).  The T117S variant exhiibits roughly 50% loss of wild-type CYB5R3’s reductase activity.  As such, in vitro studies have shown it to attenuate cGMP production by soluble guanylate cyclase (sGC) in the presence of NO donors, a problem that can be circumvented with the sGC activator Bay 58-2667. 

We developed a new sickle cell anemia (SS) mouse model that represents roughly a quarter of the sickle cell disease (SCD) patient population.  We crossed Townes AS mice with homozygous CYB5R3 T117S mice to generate SS mice that are humanized for alpha and sickle beta (betaS) globins and globally express homozygous (T117S+/+) or heterozygous (T117S+/-) CYB5R3 T117S.    We created this SST117S mouse model to capture interindividual differences in the pathological expression of SCD, as well as to explore precision medicine approaches for treating patients with SCD.  Previous studies in these patients have shown that the T117S variant associates with tempered patient response to hydroxyurea and riociguat (sGC stimulator) therapies. Preclinical studies in Townes SS mice have supported a causal role for deficient CYB5R3 expression and activity in the accelerated development of pulmonary hypertension (PH) and a tempered response to sGC stimulator Bay 41-2772 efficacy. 

Methods: We used Crispr-Cas9 to create a T117S mouse on a C57Bl6 background, which we then crossed with Townes AS mice (mixed background) to produce SS offspring with homozygous T117S (T117S+/+), heterozygous T117S (T117S+/-) and wild-type CYB5R3 (T117S-/-). The development of PH was studied in young adult male SS mice (aged 24-30 weeks) with T117S+/+, T117S+/- CYB5R3 and T117S-/- littermate controls. Closed chest right heart catheterization (Millar) was performed under etomodate/urethane (9:1.1 mg/kg i.p.) anesthesia for measurement of right ventricle systolic pressure (RVSP, mmHg) to definitively assess PH status.  Other measurements made included heart rate, complete blood counts using Hemavet, Fulton Index (right ventricle / left ventricle + septum), as well as spleen, kidney and liver weights normalized to tibia length.  A 95% confidence interval was used for unpaired t-tests between 2 groups.

Results: Right heart catheterization showed SST117S+/+ and SST117S+/- male mice had similarly elevated RVSPs (27.86 ± 3.41 mmHg and 27.63 ± 2.32 mmHg, respectively) when compared to wild-type SST117S-/- mice (16.65 ± 2.89 mmHg, p < 0.05 each).  This occurred in the presence of similar heart rates (> 400 beats per minute) in all groups. A positive relationship between the Fulton Index (T117S-/- 0.2567, T117S+/- 0.2745, T117S+/+ 0.3160) and the T117S gene copy number was detected.  Assessment of normalized organ weights did not reveal any gross differences in the kidneys, spleens or livers of the 3 groups.  Apart from white blood cells, all hematological indices were also similar between the 3 groups. Elevated monocytes (1.86 ± 0.27 vs 1.08 ± 0.14 * 103 cells, p = 0.0382) and granulocytes (4.20 ± 0.22 vs 2.57 ± 0.44 * 103 cells, p = 0.0046) were noted in the SST117S+/+ group relative to SST117S+/-.  

Conclusion: Our findings support a role for T117S CYB5R3 in promoting the development of PH in SCD.  The similarly elevated RVSPs between SS mice carrying one or both copies of the T117S variant suggests that the mutant T117S CYB5R3 allele is dominant over the wild-type CYB5R3 allele in the evolution of SS-associated PH.  The higher monocyte and granulocyte levels in the homozygous T117S carriers versus their heterozygous and wild-type counterparts suggest an enhanced inflammatory phenotype, the origin and effects of which require further mechanistic investigation.  Overall, the novel SST117S mouse represents a promising in vivo model for assessing the impact of T117S on multiple disease processes common to patients with SCD.  Importantly, the data support published clinical findings pointing to T117S as a potential biomarker for risk stratification and precision medicine approaches to clinical management of patients with SS-associated PH.  

Katherine C Wood, PhD: No relevant conflicts of interest to declare.